This clinical trial is focused on studying Crohn’s Disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The study is testing a treatment called Guselkumab, which is given as an injection under the skin. Guselkumab is a type of protein that may help reduce inflammation in the body. The trial also includes a comparison with a placebo, which is a substance with no active medication, to evaluate the effectiveness of Guselkumab.
The purpose of this study is to assess how well Guselkumab works and how safe it is for people with moderately to severely active Crohn’s Disease. Participants in the study will receive either Guselkumab or a placebo. The study will last for several weeks, during which participants will receive regular injections and attend follow-up visits to monitor their health and the effects of the treatment.
Throughout the study, researchers will look for signs of improvement in the participants’ symptoms and check for any side effects. The main goal is to see if Guselkumab can help achieve clinical remission, which means a significant reduction or disappearance of symptoms, and an endoscopic response, which is an improvement seen during an examination of the digestive tract. The study aims to provide valuable information about the potential benefits of Guselkumab for people living with Crohn’s Disease.



Croatia
Czechia
France
Germany
Hungary
Italy
Lithuania
Poland
Slovakia
Spain